• Gisela Vecchio, Valeria Zapico, Alejandro Catanzariti, Indalecio Carboni Bisso, and Marcos Las Heras.
• Farmacia, Hospital Italiano de Buenos Aires, Argentina. E-mail: gisela.vecchio@hospitalitaliano.org.ar.
• Medicina (B Aires). 2020 Jan 1; 80 (5): 439441439-441.

AbstractDuring the SARSCoV-2 pandemic many drugs have been used as potential treatments in order to improve the clinical outcome and reduce the mortality. But since it is a currently unknown disease, the evidence about efficacy and safety is built as the drugs are prescribed. In this context, intensive pharmacovigilance allows early detection of adverse events, and thereby infer the safety profile of the indication. We conducted an observational, retrospective, single-center study involving adult patients with severe SARS-CoV-2 infection. All adverse events detected in 23 patients in the Intensive Care Unit between March 15 and June 15, 2020 were registered. We describe type and severity of the adverse events and if treatment suspension was needed. The results show a high rate of adverse events (10/23, 43%) in treatment with lopinavir/ritonavir. In most cases early treatment suspension was required. Even though the limitations of our study derived from the small sample size, these results could help in building evidence about the safety of using lopinavir/ritonavir for severe SARS-CoV-2 infection.

34 keywords...

hide…